Global Diabetic Foot Ulcer (DFU) Therapeutic 麻豆原创 2024 by Company, Regions, Type and Application, Forecast to 2030

Publication ID:

GIR092415896

Publication Date:

September 24, 2024

Pages:

Publisher:

GIR

Countries:

Global [1]

USD 3,480.00

Medical Devices [2]

Pharma & Healthcare [3]

Description:

Diabetic foot ulcer听is a major complication of听diabetes听mellitus, and probably the major component of the听diabetic foot. Diabetic foot ulcers are among one of the major global medical issues. Management of diabetic foot ulcers aims at fast healing and wound closure, by adopting a multidisciplinary therapeutic approach so as to avoid amputation.
The global Diabetic Foot Ulcer (DFU) Therapeutic market size was valued at US$ 5092 million in 2023 and is forecast to a readjusted size of USD 7694 million by 2030 with a CAGR of 6.1% during review period.
Global main players in the diabetic foot ulcer (DFU) therapeutic industry are 3M, Smith & Nephew, Molnlycke Health Care, account for about a third of market share in total. Geographically speaking, North America is the largest market, accounting for about 40% of total market share, followed by Europe with a share of over 30%. In terms of type, wound care dressing segment holds an important share of over 50%. In terms of application, neuro-ischemic ulcers holds about 50% share.
This report is a detailed and comprehensive analysis for global Diabetic Foot Ulcer (DFU) Therapeutic market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2024, are provided.
Key Features:
Global Diabetic Foot Ulcer (DFU) Therapeutic market size and forecasts, in consumption value ($ Million), 2019-2030
Global Diabetic Foot Ulcer (DFU) Therapeutic market size and forecasts by region and country, in consumption value ($ Million), 2019-2030
Global Diabetic Foot Ulcer (DFU) Therapeutic market size and forecasts, by Type and by Application, in consumption value ($ Million), 2019-2030
Global Diabetic Foot Ulcer (DFU) Therapeutic market shares of main players, in revenue ($ Million), 2019-2024
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Diabetic Foot Ulcer (DFU) Therapeutic
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Diabetic Foot Ulcer (DFU) Therapeutic market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include 3M, Smith & Nephew, Molnlycke Health Care, ConvaTec, Coloplast, Integra LifeSciences, Essity (BSN Medical), Medline, B. Braun, Organogenesis, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
麻豆原创 segmentation
Diabetic Foot Ulcer (DFU) Therapeutic market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
麻豆原创 segmentation
Diabetic Foot Ulcer (DFU) Therapeutic market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
麻豆原创 segment by Type
Wound Care Dressing
Biologics
Therapy Devices
Antibiotic Medications
Others
麻豆原创 segment by Application
Neuropathic Ulcers
Ischemic Ulcers
Neuro-ischemic Ulcers
麻豆原创 segment by players, this report covers
3M
Smith & Nephew
Molnlycke Health Care
ConvaTec
Coloplast
Integra LifeSciences
Essity (BSN Medical)
Medline
B. Braun
Organogenesis
麻豆原创 segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Diabetic Foot Ulcer (DFU) Therapeutic product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Diabetic Foot Ulcer (DFU) Therapeutic, with revenue, gross margin, and global market share of Diabetic Foot Ulcer (DFU) Therapeutic from 2019 to 2024.
Chapter 3, the Diabetic Foot Ulcer (DFU) Therapeutic competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2019 to 2030.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2019 to 2024.and Diabetic Foot Ulcer (DFU) Therapeutic market forecast, by regions, by Type and by Application, with consumption value, from 2024 to 2030.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Diabetic Foot Ulcer (DFU) Therapeutic.
Chapter 13, to describe Diabetic Foot Ulcer (DFU) Therapeutic research findings and conclusion.

Please Note - This is an on demand report and will be delivered in 2 business days (48 Hours) post payment.

Table Of Contents:

1 麻豆原创 Overview
1.1 Product Overview and Scope
1.2 麻豆原创 Estimation Caveats and Base Year
1.3 Classification of Diabetic Foot Ulcer (DFU) Therapeutic by Type
1.3.1 Overview: Global Diabetic Foot Ulcer (DFU) Therapeutic 麻豆原创 Size by Type: 2019 Versus 2023 Versus 2030
1.3.2 Global Diabetic Foot Ulcer (DFU) Therapeutic Consumption Value 麻豆原创 Share by Type in 2023
1.3.3 Wound Care Dressing
1.3.4 Biologics
1.3.5 Therapy Devices
1.3.6 Antibiotic Medications
1.3.7 Others
1.4 Global Diabetic Foot Ulcer (DFU) Therapeutic 麻豆原创 by Application
1.4.1 Overview: Global Diabetic Foot Ulcer (DFU) Therapeutic 麻豆原创 Size by Application: 2019 Versus 2023 Versus 2030
1.4.2 Neuropathic Ulcers
1.4.3 Ischemic Ulcers
1.4.4 Neuro-ischemic Ulcers
1.5 Global Diabetic Foot Ulcer (DFU) Therapeutic 麻豆原创 Size & Forecast
1.6 Global Diabetic Foot Ulcer (DFU) Therapeutic 麻豆原创 Size and Forecast by Region
1.6.1 Global Diabetic Foot Ulcer (DFU) Therapeutic 麻豆原创 Size by Region: 2019 VS 2023 VS 2030
1.6.2 Global Diabetic Foot Ulcer (DFU) Therapeutic 麻豆原创 Size by Region, (2019-2030)
1.6.3 North America Diabetic Foot Ulcer (DFU) Therapeutic 麻豆原创 Size and Prospect (2019-2030)
1.6.4 Europe Diabetic Foot Ulcer (DFU) Therapeutic 麻豆原创 Size and Prospect (2019-2030)
1.6.5 Asia-Pacific Diabetic Foot Ulcer (DFU) Therapeutic 麻豆原创 Size and Prospect (2019-2030)
1.6.6 South America Diabetic Foot Ulcer (DFU) Therapeutic 麻豆原创 Size and Prospect (2019-2030)
1.6.7 Middle East & Africa Diabetic Foot Ulcer (DFU) Therapeutic 麻豆原创 Size and Prospect (2019-2030)
2 Company Profiles
2.1 3M
2.1.1 3M Details
2.1.2 3M Major Business
2.1.3 3M Diabetic Foot Ulcer (DFU) Therapeutic Product and Solutions
2.1.4 3M Diabetic Foot Ulcer (DFU) Therapeutic Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.1.5 3M Recent Developments and Future Plans
2.2 Smith & Nephew
2.2.1 Smith & Nephew Details
2.2.2 Smith & Nephew Major Business
2.2.3 Smith & Nephew Diabetic Foot Ulcer (DFU) Therapeutic Product and Solutions
2.2.4 Smith & Nephew Diabetic Foot Ulcer (DFU) Therapeutic Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.2.5 Smith & Nephew Recent Developments and Future Plans
2.3 Molnlycke Health Care
2.3.1 Molnlycke Health Care Details
2.3.2 Molnlycke Health Care Major Business
2.3.3 Molnlycke Health Care Diabetic Foot Ulcer (DFU) Therapeutic Product and Solutions
2.3.4 Molnlycke Health Care Diabetic Foot Ulcer (DFU) Therapeutic Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.3.5 Molnlycke Health Care Recent Developments and Future Plans
2.4 ConvaTec
2.4.1 ConvaTec Details
2.4.2 ConvaTec Major Business
2.4.3 ConvaTec Diabetic Foot Ulcer (DFU) Therapeutic Product and Solutions
2.4.4 ConvaTec Diabetic Foot Ulcer (DFU) Therapeutic Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.4.5 ConvaTec Recent Developments and Future Plans
2.5 Coloplast
2.5.1 Coloplast Details
2.5.2 Coloplast Major Business
2.5.3 Coloplast Diabetic Foot Ulcer (DFU) Therapeutic Product and Solutions
2.5.4 Coloplast Diabetic Foot Ulcer (DFU) Therapeutic Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.5.5 Coloplast Recent Developments and Future Plans
2.6 Integra LifeSciences
2.6.1 Integra LifeSciences Details
2.6.2 Integra LifeSciences Major Business
2.6.3 Integra LifeSciences Diabetic Foot Ulcer (DFU) Therapeutic Product and Solutions
2.6.4 Integra LifeSciences Diabetic Foot Ulcer (DFU) Therapeutic Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.6.5 Integra LifeSciences Recent Developments and Future Plans
2.7 Essity (BSN Medical)
2.7.1 Essity (BSN Medical) Details
2.7.2 Essity (BSN Medical) Major Business
2.7.3 Essity (BSN Medical) Diabetic Foot Ulcer (DFU) Therapeutic Product and Solutions
2.7.4 Essity (BSN Medical) Diabetic Foot Ulcer (DFU) Therapeutic Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.7.5 Essity (BSN Medical) Recent Developments and Future Plans
2.8 Medline
2.8.1 Medline Details
2.8.2 Medline Major Business
2.8.3 Medline Diabetic Foot Ulcer (DFU) Therapeutic Product and Solutions
2.8.4 Medline Diabetic Foot Ulcer (DFU) Therapeutic Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.8.5 Medline Recent Developments and Future Plans
2.9 B. Braun
2.9.1 B. Braun Details
2.9.2 B. Braun Major Business
2.9.3 B. Braun Diabetic Foot Ulcer (DFU) Therapeutic Product and Solutions
2.9.4 B. Braun Diabetic Foot Ulcer (DFU) Therapeutic Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.9.5 B. Braun Recent Developments and Future Plans
2.10 Organogenesis
2.10.1 Organogenesis Details
2.10.2 Organogenesis Major Business
2.10.3 Organogenesis Diabetic Foot Ulcer (DFU) Therapeutic Product and Solutions
2.10.4 Organogenesis Diabetic Foot Ulcer (DFU) Therapeutic Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.10.5 Organogenesis Recent Developments and Future Plans
3 麻豆原创 Competition, by Players
3.1 Global Diabetic Foot Ulcer (DFU) Therapeutic Revenue and Share by Players (2019-2024)
3.2 麻豆原创 Share Analysis (2023)
3.2.1 麻豆原创 Share of Diabetic Foot Ulcer (DFU) Therapeutic by Company Revenue
3.2.2 Top 3 Diabetic Foot Ulcer (DFU) Therapeutic Players 麻豆原创 Share in 2023
3.2.3 Top 6 Diabetic Foot Ulcer (DFU) Therapeutic Players 麻豆原创 Share in 2023
3.3 Diabetic Foot Ulcer (DFU) Therapeutic 麻豆原创: Overall Company Footprint Analysis
3.3.1 Diabetic Foot Ulcer (DFU) Therapeutic 麻豆原创: Region Footprint
3.3.2 Diabetic Foot Ulcer (DFU) Therapeutic 麻豆原创: Company Product Type Footprint
3.3.3 Diabetic Foot Ulcer (DFU) Therapeutic 麻豆原创: Company Product Application Footprint
3.4 New 麻豆原创 Entrants and Barriers to 麻豆原创 Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 麻豆原创 Size Segment by Type
4.1 Global Diabetic Foot Ulcer (DFU) Therapeutic Consumption Value and 麻豆原创 Share by Type (2019-2024)
4.2 Global Diabetic Foot Ulcer (DFU) Therapeutic 麻豆原创 Forecast by Type (2025-2030)
5 麻豆原创 Size Segment by Application
5.1 Global Diabetic Foot Ulcer (DFU) Therapeutic Consumption Value 麻豆原创 Share by Application (2019-2024)
5.2 Global Diabetic Foot Ulcer (DFU) Therapeutic 麻豆原创 Forecast by Application (2025-2030)
6 North America
6.1 North America Diabetic Foot Ulcer (DFU) Therapeutic Consumption Value by Type (2019-2030)
6.2 North America Diabetic Foot Ulcer (DFU) Therapeutic 麻豆原创 Size by Application (2019-2030)
6.3 North America Diabetic Foot Ulcer (DFU) Therapeutic 麻豆原创 Size by Country
6.3.1 North America Diabetic Foot Ulcer (DFU) Therapeutic Consumption Value by Country (2019-2030)
6.3.2 United States Diabetic Foot Ulcer (DFU) Therapeutic 麻豆原创 Size and Forecast (2019-2030)
6.3.3 Canada Diabetic Foot Ulcer (DFU) Therapeutic 麻豆原创 Size and Forecast (2019-2030)
6.3.4 Mexico Diabetic Foot Ulcer (DFU) Therapeutic 麻豆原创 Size and Forecast (2019-2030)
7 Europe
7.1 Europe Diabetic Foot Ulcer (DFU) Therapeutic Consumption Value by Type (2019-2030)
7.2 Europe Diabetic Foot Ulcer (DFU) Therapeutic Consumption Value by Application (2019-2030)
7.3 Europe Diabetic Foot Ulcer (DFU) Therapeutic 麻豆原创 Size by Country
7.3.1 Europe Diabetic Foot Ulcer (DFU) Therapeutic Consumption Value by Country (2019-2030)
7.3.2 Germany Diabetic Foot Ulcer (DFU) Therapeutic 麻豆原创 Size and Forecast (2019-2030)
7.3.3 France Diabetic Foot Ulcer (DFU) Therapeutic 麻豆原创 Size and Forecast (2019-2030)
7.3.4 United Kingdom Diabetic Foot Ulcer (DFU) Therapeutic 麻豆原创 Size and Forecast (2019-2030)
7.3.5 Russia Diabetic Foot Ulcer (DFU) Therapeutic 麻豆原创 Size and Forecast (2019-2030)
7.3.6 Italy Diabetic Foot Ulcer (DFU) Therapeutic 麻豆原创 Size and Forecast (2019-2030)
8 Asia-Pacific
8.1 Asia-Pacific Diabetic Foot Ulcer (DFU) Therapeutic Consumption Value by Type (2019-2030)
8.2 Asia-Pacific Diabetic Foot Ulcer (DFU) Therapeutic Consumption Value by Application (2019-2030)
8.3 Asia-Pacific Diabetic Foot Ulcer (DFU) Therapeutic 麻豆原创 Size by Region
8.3.1 Asia-Pacific Diabetic Foot Ulcer (DFU) Therapeutic Consumption Value by Region (2019-2030)
8.3.2 China Diabetic Foot Ulcer (DFU) Therapeutic 麻豆原创 Size and Forecast (2019-2030)
8.3.3 Japan Diabetic Foot Ulcer (DFU) Therapeutic 麻豆原创 Size and Forecast (2019-2030)
8.3.4 South Korea Diabetic Foot Ulcer (DFU) Therapeutic 麻豆原创 Size and Forecast (2019-2030)
8.3.5 India Diabetic Foot Ulcer (DFU) Therapeutic 麻豆原创 Size and Forecast (2019-2030)
8.3.6 Southeast Asia Diabetic Foot Ulcer (DFU) Therapeutic 麻豆原创 Size and Forecast (2019-2030)
8.3.7 Australia Diabetic Foot Ulcer (DFU) Therapeutic 麻豆原创 Size and Forecast (2019-2030)
9 South America
9.1 South America Diabetic Foot Ulcer (DFU) Therapeutic Consumption Value by Type (2019-2030)
9.2 South America Diabetic Foot Ulcer (DFU) Therapeutic Consumption Value by Application (2019-2030)
9.3 South America Diabetic Foot Ulcer (DFU) Therapeutic 麻豆原创 Size by Country
9.3.1 South America Diabetic Foot Ulcer (DFU) Therapeutic Consumption Value by Country (2019-2030)
9.3.2 Brazil Diabetic Foot Ulcer (DFU) Therapeutic 麻豆原创 Size and Forecast (2019-2030)
9.3.3 Argentina Diabetic Foot Ulcer (DFU) Therapeutic 麻豆原创 Size and Forecast (2019-2030)
10 Middle East & Africa
10.1 Middle East & Africa Diabetic Foot Ulcer (DFU) Therapeutic Consumption Value by Type (2019-2030)
10.2 Middle East & Africa Diabetic Foot Ulcer (DFU) Therapeutic Consumption Value by Application (2019-2030)
10.3 Middle East & Africa Diabetic Foot Ulcer (DFU) Therapeutic 麻豆原创 Size by Country
10.3.1 Middle East & Africa Diabetic Foot Ulcer (DFU) Therapeutic Consumption Value by Country (2019-2030)
10.3.2 Turkey Diabetic Foot Ulcer (DFU) Therapeutic 麻豆原创 Size and Forecast (2019-2030)
10.3.3 Saudi Arabia Diabetic Foot Ulcer (DFU) Therapeutic 麻豆原创 Size and Forecast (2019-2030)
10.3.4 UAE Diabetic Foot Ulcer (DFU) Therapeutic 麻豆原创 Size and Forecast (2019-2030)
11 麻豆原创 Dynamics
11.1 Diabetic Foot Ulcer (DFU) Therapeutic 麻豆原创 Drivers
11.2 Diabetic Foot Ulcer (DFU) Therapeutic 麻豆原创 Restraints
11.3 Diabetic Foot Ulcer (DFU) Therapeutic Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 Industry Chain Analysis
12.1 Diabetic Foot Ulcer (DFU) Therapeutic Industry Chain
12.2 Diabetic Foot Ulcer (DFU) Therapeutic Upstream Analysis
12.3 Diabetic Foot Ulcer (DFU) Therapeutic Midstream Analysis
12.4 Diabetic Foot Ulcer (DFU) Therapeutic Downstream Analysis
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer

Companies Mentioned:

3M
Smith & Nephew
Molnlycke Health Care
ConvaTec
Coloplast
Integra LifeSciences
Essity (BSN Medical)
Medline
B. Braun
Organogenesis

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.